[ad_1]
Sabine the company(NEO: CYBN) (Over-the-counter market:CLXPF) (“Sabine“Or”the company“), a biotechnology company focused on advancing psychedelic therapy, today announced that CEO Doug Drysdale will deliver a speech at the HC Wainwright Psychedelics in Psychiatry and Beyond virtual conference on June 17, 2021. The details of the speech are as follows:
The presentation will be webcast on demand and can be viewed using the link provided above within 90 days thereafter.
Mr. Drysdale will also participate in a panel discussion at 9:00 am Eastern Time: Disruptive Psychopharmacology-Introduction to Psychedelic Drugs and the Coming Psychiatric Revolution.
About Sabine
Cybin is a leading biotechnology company focused on advancing psychedelic therapy through the use of proprietary drug discovery platforms, innovative drug delivery systems, novel formulation methods, and mental illness treatment options.
Cautions and forward-looking statements
Certain statements related to the company in this press release are forward-looking statements and are forward-looking. Forward-looking statements are not based on historical facts, but are based on current expectations and predictions of future events, and are therefore subject to risks and uncertainties that may lead to actual results and the future expressed or implied by forward-looking statements The results are materially different. These statements can usually be forward-looking using such as “may”, “should”, “may”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, etc. Words to identify “or “continue”, or deny or similar changes. The forward-looking statements in this press release include information about enhanced liquidity, the value of additional capital market risk exposure, opportunities to reach institutions and retail investors, and company new Statements on the strategic branding campaigns and development plans of psychedelic drugs for potential treatment of mental health disorders. There are many risks and uncertainties that may cause actual results and Cybin’s plans and goals to differ materially from those expressed in forward-looking information. Actual Results and future events may differ materially from those expected in such information. These and all subsequent written and oral forward-looking information are based on management’s estimates and opinions on the date of its release, and all of them are clearly defined in this notice. Content. Except as required by law, the company does not intend to update these forward-looking statements.
Cybin does not make any medical, therapeutic or health benefit claims for the products proposed by Cybin. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory agencies have not yet evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals. The efficacy of such products has not been confirmed by approved studies. There is no guarantee that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutrients can diagnose, treat, cure or prevent any disease or condition. It is necessary to vigorously carry out scientific research and clinical trials. Cybin has not yet conducted clinical trials for the use of its proposed products. Any mention of the quality, consistency, effectiveness and safety of potential products does not mean that Cybin has verified these in clinical trials or that Cybin will complete such trials. If Cybin is unable to obtain the approval or research required to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
NEO Exchange neither endorses nor denies the content of this press release, and assumes no responsibility for the adequacy and accuracy of the content.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210611005442/en/
[ad_2]
Source link
